Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1993-02-02
1994-05-10
Nucker, Christine M.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 792, 424 88, 530358, 5303877, 5303888, 5303897, G01N 33574, A61K 3900, A61K 3708, C07K 1518
Patent
active
053106539
ABSTRACT:
A tumor-associated marker protein was purified and antibodies thereto developed for cancer diagnosis and assessment of cancer risk associated with the long-term use of synthetic steroid hormones, both contraceptive and non-contraceptive, and other drugs that exhibit tumor promotional properties. The marker protein and antibodies thereto provided are interspecies immunologically cross-reactive.
In summary, the marker p65 tumor-associated factor of the present invention has the following characteristics:
REFERENCES:
patent: 4448890 (1984-05-01), Smetana et al.
patent: 4746539 (1988-05-01), Webb et al.
Hamausek-Walaszek et al., Progress in Clinical and Biological Research (1989).
Hanausek-Walaszek et al., "Carcinogenesis", Proceedings of the American Association for Cancer Research 30:190, Abstract 754 (1989).
Larroya et al., "Immunology", Proceedings of the American Association for Cancer Research 30:349, Abstract 1385 (1989).
Hanausesk-Walaszek et al., "Carcinogenesis", Proceedings of AACR 29:167, Abstract 665 (1988).
Hanausek-Walaszek et al., "Correspondence Between Biochemical and Antigenic Activity of a 60 Kilodalton Oncofetal Protein During Carcinogenesis and Tumorigenesis," Cancer Letters 33:55-61 (1986).
Hanausek-Walaszek et al., "A 60 Kilodalton Oncofetal Protein As Tumor Marker," J. Med. 17:13-23 (1986).
Schroder et al., "Proteins from rat liver cytosol which stimulate mRNA transport," Eur. J. Biochem. 159:51-59 (1986).
Hanausek-Walaszek et al., "Immunological Identity of a 60 KD Oncofetal Protein Induced in Rats by Chemical Carcinogens and Released by Transformed Cells," BBRC 127:779-785 (1985).
Hanausek-Walaszek et al., "Chemical carcinogens as specific inducers of a 60-kilodalton oncofetal protein in rats," Carcinogenesis 7:1725-1730 (1985).
Schumm et al., "Absence of the Cancer-associated Factor with a Molecular Weight of 60,000 from the Plasma of Patients with a Spectrum of Nonneoplastic Conditions," Cancer Res. 44:401-406 (1984).
Hanausek-Walaszek et al., "Characterization of a 60,000-dalton Oncofetal Protein from the Plasma of Tumor-Bearing Rats," Cancer Invest. 2:433-441 (1984).
French et al., "Nucleocytoplasmic Release of Pepetitive DNA Transcripts in Carcinogenesis Correlates with a 60 Kilodalton Cytoplasmic Protein," Cancer Letters 23:45-52 (1984).
Walaszek et al., "An Oncofetal 60-Kilodalton Protein in the Plasma of Tumor-Bearing and Carcinogen-Treated Rats," Cancer Letters 20:277-282 (1983).
Hanausek-Walaszek et al., "Structural and Immunological Identity of p, 65 Tumor-Associated Factors from Rat and Mouse Hepatocarcinomas," Progress in Clinical and Biological Ressearch (1989).
Hanausek-Walaszek Margaret
Slaga Thomas J.
Walaszek Zbigniew
Board of Regents , The University of Texas System
Nucker Christine M.
Woodward M. P.
LandOfFree
Tumor marker protein and antibodies thereto for cancer risk asse does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor marker protein and antibodies thereto for cancer risk asse, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor marker protein and antibodies thereto for cancer risk asse will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2412034